-
1
-
-
0033542845
-
Cancer in patients on dialysis for end-stage renal disease: An international collaborative study
-
Maisonneuve P, Agodoa L, Gellert R, et al. Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet 1999;354:93-99.
-
(1999)
Lancet
, vol.354
, pp. 93-99
-
-
Maisonneuve, P.1
Agodoa, L.2
Gellert, R.3
-
2
-
-
17844372539
-
Critical update and emerging trends in epidermal growth factor receptor targeting in cancer
-
Baselga J, Arteaga CL. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 2005;23:2445-2459.
-
(2005)
J Clin Oncol
, vol.23
, pp. 2445-2459
-
-
Baselga, J.1
Arteaga, C.L.2
-
3
-
-
22044445517
-
Erlotinib in previously treated non-small-cell lung cancer
-
Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353: 123-132.
-
(2005)
N Engl J Med
, vol.353
, pp. 123-132
-
-
Shepherd, F.A.1
Rodrigues Pereira, J.2
Ciuleanu, T.3
-
4
-
-
33947504732
-
Phase II clinical trial of chemotherapy-naive patients- or- 70 years of age treated with erlotinib for advanced non-small-cell lung cancer
-
Jackman DM, Yeap BY, Lindeman NI, et al. Phase II clinical trial of chemotherapy-naive patients- or- 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol 2007; 25:760-766.
-
(2007)
J Clin Oncol
, vol.25
, pp. 760-766
-
-
Jackman, D.M.1
Yeap, B.Y.2
Lindeman, N.I.3
-
5
-
-
58149132477
-
Southwest Oncology Group phase II trial (S0341) of erlotinib (OSI-774) in patients with advanced non-small cell lung cancer and a performance status of 2
-
Hesketh PJ, Chansky K, Wozniak AJ, et al. Southwest Oncology Group phase II trial (S0341) of erlotinib (OSI-774) in patients with advanced non-small cell lung cancer and a performance status of 2. J Thorac Oncol 2008;3:1026-1031.
-
(2008)
J Thorac Oncol
, vol.3
, pp. 1026-1031
-
-
Hesketh, P.J.1
Chansky, K.2
Wozniak, A.J.3
-
6
-
-
39749087795
-
Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-smallcell lung cancer and a performance status of 2
-
Lilenbaum R, Axelrod R, Thomas S, et al. Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-smallcell lung cancer and a performance status of 2. J Clin Oncol 2008;26: 863-869.
-
(2008)
J Clin Oncol
, vol.26
, pp. 863-869
-
-
Lilenbaum, R.1
Axelrod, R.2
Thomas, S.3
-
7
-
-
44249121733
-
Erlotinib for advanced non-small-cell lung cancer in the elderly: An analysis of the National Cancer Institute of Canada clinical trials group study BR. 21
-
Wheatley-Price P, Ding K, Seymour L, et al. Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR. 21. J Clin Oncol 2008;26:2350-2357.
-
(2008)
J Clin Oncol
, vol.26
, pp. 2350-2357
-
-
Wheatley-Price, P.1
Ding, K.2
Seymour, L.3
-
8
-
-
34249733299
-
Safety profile of erlotinib in patients with advanced non-small cell lung cancer with chronic renal failure
-
Gridelli C, Maione P, Galetta D, et al. Safety profile of erlotinib in patients with advanced non-small cell lung cancer with chronic renal failure. J Thorac Oncol 2007;2:96-98.
-
(2007)
J Thorac Oncol
, vol.2
, pp. 96-98
-
-
Gridelli, C.1
Maione, P.2
Galetta, D.3
-
9
-
-
34547701893
-
Phase i and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101
-
Miller AA, Murry DJ, Owzar K, et al. Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101. J Clin Oncol 2007;25:3055-3060.
-
(2007)
J Clin Oncol
, vol.25
, pp. 3055-3060
-
-
Miller, A.A.1
Murry, D.J.2
Owzar, K.3
-
10
-
-
10944226719
-
Simultaneous determination of OSI-774 and its major metabolite OSI-420 in human plasma by using HPLC with UV detection
-
Zhang W, Siu LL, Moore MJ, et al. Simultaneous determination of OSI-774 and its major metabolite OSI-420 in human plasma by using HPLC with UV detection. J Chromatogr B Analyt Technol Biomed Life Sci 2005;814:143-147.
-
(2005)
J Chromatogr B Analyt Technol Biomed Life Sci
, vol.814
, pp. 143-147
-
-
Zhang, W.1
Siu, L.L.2
Moore, M.J.3
-
11
-
-
37249041552
-
Phase i dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors
-
Yamamoto N, Horiike A, Fujisaka Y, et al. Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors. Cancer Chemother Pharmacol 2008;61:489-496.
-
(2008)
Cancer Chemother Pharmacol
, vol.61
, pp. 489-496
-
-
Yamamoto, N.1
Horiike, A.2
Fujisaka, Y.3
-
12
-
-
0038343126
-
Pharmacokinetics and pharmacodynamics: Maximizing the clinical potential of Erlotinib (Tarceva)
-
Hidalgo M, Bloedow D. Pharmacokinetics and pharmacodynamics: maximizing the clinical potential of Erlotinib (Tarceva). Semin Oncol 2003;30(3 suppl 7):25-33.
-
(2003)
Semin Oncol
, vol.30
, Issue.3 SUPPL. 7
, pp. 25-33
-
-
Hidalgo, M.1
Bloedow, D.2
-
13
-
-
0030774045
-
Induction of apoptosis and cell cycle arrest by CP-358, 774, an inhibitor of epidermal growth factor receptor tyrosine kinase
-
Moyer JD, Barbacci EG, Iwata KK, et al. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 1997;57:4838-4848.
-
(1997)
Cancer Res
, vol.57
, pp. 4838-4848
-
-
Moyer, J.D.1
Barbacci, E.G.2
Iwata, K.K.3
-
14
-
-
0032695910
-
Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358, 774: Dynamics of receptor inhibition in situ and antitumor effects in athymic mice
-
Pollack VA, Savage DM, Baker DA, et al. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J Pharmacol Exp Ther 1999;291: 739-748.
-
(1999)
J Pharmacol Exp Ther
, vol.291
, pp. 739-748
-
-
Pollack, V.A.1
Savage, D.M.2
Baker, D.A.3
-
15
-
-
33646238486
-
Effects of smoking on the pharmacokinetics of erlotinib
-
Hamilton M, Wolf JL, Rusk J, et al. Effects of smoking on the pharmacokinetics of erlotinib. Clin Cancer Res 2006;12(7 Pt 1):2166-2171.
-
(2006)
Clin Cancer Res
, vol.12
, Issue.7 PART 1
, pp. 2166-2171
-
-
Hamilton, M.1
Wolf, J.L.2
Rusk, J.3
-
16
-
-
58149181583
-
Overview of regular dialysis treatment in Japan as of 31 Decembe 2006
-
Nakai S, Masakane I, Akiba T, et al. Overview of regular dialysis treatment in Japan as of 31 December 2006. Ther Apher Dial 2008;12: 428-456.
-
(2008)
Ther Apher Dial
, vol.12
, pp. 428-456
-
-
Nakai, S.1
Masakane, I.2
Akiba, T.3
-
17
-
-
34948911363
-
End-stage renal disease in the United States: An update from the United States Renal Data System
-
Foley RN, Collins AJ. End-stage renal disease in the United States: an update from the United States Renal Data System. J Am Soc Nephrol 2007;18:2644-2648.
-
(2007)
J Am Soc Nephrol
, vol.18
, pp. 2644-2648
-
-
Foley, R.N.1
Collins, A.J.2
|